Overall rank by patents
#31,742
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView Foreign Corporation
Genereach Biotechnology Corporation
USPTO PatentsView assignee record - 8 granted patents across 5 technology areas, active 2016–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: B01L (CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE).
8
Total patents granted
5
CPC technology areas
7.8
Avg claims per patent
+0%
5-year filing velocity
The verdict
Genereach holds 8 US patents across 5 technology areas, rank #31,742 of 50,000 tracked assignees.
- #31,742
- of 50,000 US assignees by volume
- Top 55%
- by Innovation Score (33.5/100)
- 7.8
- avg claims per patent
- +0%
- filing velocity, last 5 yrs
Portfolio overview
Genereach Biotechnology Corporation has been granted 8 US utility patents between 2016 and 2025, placing Genereach Biotechnology Corporation at rank #31,742 across all assignees tracked by PlainPatent. This portfolio spans 5 distinct Cooperative Patent Classification (CPC) subclasses, averaging 7.8 claims per patent with primary concentration in B01L (CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE). As a Foreign Corporation, Genereach Biotechnology Corporation is one of the more focused assignees in the PatentsView dataset. By volume, Genereach sits between Gen1e Lifesciences Inc. (8 patents, rank #31,738) and Getas Gesellschaft Für Thermodynamische Antriebssysteme Mbh (8 patents, rank #31,746) - the closest US assignees by grant volume. The composite Innovation Score of 33.5/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 4 grants, compared with 4 in the 2015–2019 window, a +0% shift in five-year velocity. Steady filing volume suggests sustained innovation without dramatic pivots. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Genereach Biotechnology Corporation's 7.8 average claims per patent suggests focused, narrowly drawn claims typical of single-invention filings, while concentration in 5 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Genereach Biotechnology Corporation against peers pursuing similar technology classes.
Who files at Genereach's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Gen1e Lifesciences
GEN1E LIFESCIENCES INC.
8 patents
- GENE Stream PTY
GENE STREAM PTY LTD.
8 patents
- General Plasma
GENERAL PLASMA INC.
8 patents
- General Printing…
GENERAL PRINTING & DESIGN, INC.
8 patents
- Genesis Technical…
GENESIS TECHNICAL SYSTEMS CORP.
8 patents
- Geneuro
GENEURO SA
8 patents
- Georgia-pacific N…
GEORGIA-PACIFIC NONWOVENS LLC
8 patents
- Getas Gesellschaf…
GETAS Gesellschaft für thermodynamische Antriebssysteme mbH
8 patents
- Genereach Biotech… ◀
GENEREACH BIOTECHNOLOGY CORPORATION
8 patents
What this shows Genereach holds 8 patents at rank #31,742, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Genereach
By rank, the assignees closest to #31,742 in granted patent volume.
- Gen1e Lifesciences Inc. #31,738 · 8 patents
- GENE Stream PTY Ltd. #31,739 · 8 patents
- General Plasma Inc. #31,740 · 8 patents
- General Printing & Design, Inc. #31,741 · 8 patents
- Genesis Technical Systems Corp. #31,743 · 8 patents
- Geneuro Sa #31,744 · 8 patents
- Georgia-pacific Nonwovens Llc #31,745 · 8 patents
- Getas Gesellschaft Für Thermodynamische Antriebssysteme Mbh #31,746 · 8 patents
Leaders in B01L (Chemical OR Physical Laboratory Apparatus FOR General USE)
Other assignees with the most granted patents in Genereach's primary technology class.
- The Regents Of The University Of California 239 in class
- Illumina, Inc. 232 in class
- Becton, Dickinson And Company 193 in class
- Bio-rad Laboratories, Inc. 174 in class
- President And Fellows Of Harvard College 165 in class
- Life Technologies Corporation 158 in class
- Roche Diagnostics Operations, Inc. 141 in class
- Siemens Healthcare Diagnostics Inc. 119 in class
Genereach's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
33 Top 55% higher than 45% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2016 | 2 | 25.0% |
| 2017 | 1 | 12.5% |
| 2018 | 1 | 12.5% |
| 2022 | 2 | 25.0% |
| 2025 | 2 | 25.0% |
Which technologies does Genereach Biotechnology Corporation patent most?
Top 5 of 5 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Focused
Claim Depth Simple
Velocity Growing
Frequently Asked Questions
How many patents does Genereach Biotechnology Corporation hold?
Genereach Biotechnology Corporation holds 8 US granted patents filed between 2016 and 2025, spanning 5 technology areas.
What is Genereach Biotechnology Corporation's Innovation Score?
Genereach Biotechnology Corporation has an Innovation Score of 33.5 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Genereach Biotechnology Corporation focus on?
Genereach Biotechnology Corporation's top technology area is B01L (CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE) with 5 patents. The company has filed patents in 5 CPC subclasses total.
Is Genereach Biotechnology Corporation's patent filing rate increasing or decreasing?
Genereach Biotechnology Corporation's recent filing velocity is +0% compared to the prior five-year period. The company is maintaining or growing its patent output.
What does claim depth mean for Genereach Biotechnology Corporation's patents?
Genereach Biotechnology Corporation's patents average 7.8 claims each. This is relatively simple claim structure, typical for focused inventions.
How is the Genereach Biotechnology Corporation patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Genereach's 8 grants land it in the top 55% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Genereach ranks #31,742 of 50,000. Top 50 holders
- Most of this portfolio concentrates in B01L - see who else leads that technology area. B01L leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.